31.2 C
New York
Thursday, July 3, 2025

Tag: Anna

newssourcecompanyFORcontentinformation1marketbusiness

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

DRC Medicine Ltd. Announces the Business Combination Agreement with Ribbon Acquisition Corp.

Combined Company Expected to be Listed on NASDAQ Global Market

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the “AGSM”) held today.

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

Company announcement – No. 16 / 2025

INTEGRA REPORTS VOTING RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

TSXV:ITR ; NYSE American: ITRGwww.integraresources.com VANCOUVER, BC, June 27, 2025 /PRNewswire/ - Integra Resources Corp. ("Integra" or the "Company") (TSXV: ITR) (NYSE American: ITRG) is...

INTEGRA REPORTS VOTING RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

TSXV:ITR ; NYSE American: ITRGwww.integraresources.com VANCOUVER, BC, June 27, 2025 /CNW/ - Integra Resources Corp. ("Integra" or the "Company") (TSXV: ITR) (NYSE American: ITRG) is...

Family Fun Shrinks for Summer with Lil McDonald’s

On July 1, fans across the U.S. can bring a pocket-size piece of McDonald's home with one of 21 miniature toys CHICAGO, June 25,...

Scania to supply 60 new battery-electric city buses to the South Australian state government

Landmark agreement builds on Scania's existing strong relationship with South Australia, and contributes significantly to the state's sustainability and electrification targets. SÖDERTÄLJE, Sweden, June 25, 2025 /PRNewswire/...

Specialty Food Association Announces Fancy Food Rising Stars

Selections for Summer 2025, Recognizing the Emerging Specialty Food Buyers and Investors NEW YORK, June 23, 2025 /PRNewswire/ -- The Specialty Food Association has selected...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

EPH European Property Holdings PLC Announces Change in Shareholder Structure

23 June 2025, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company.

ICPO Foundation ist Co-Founder der RLT Angels Association mit dem Ziel, den Zugang zur Radiotheranostik für eine Million PatientInnen auszubauen

Weitere Gründungsmitglieder sind die European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis und RayzeBio, ein Unternehmen von Bristol Myers Squibb.

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAnna

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers